The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding ...
Earlier this year, FDA approved Pfizer’s Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or ...
The FDA has approved Hympavzi to prevent bleeding episodes in hemophilia A and B patients aged 12 and older. This innovative ...
Pfizer CEO Albert Bourla is in a tough spot as activist investor Starboard Value continues to call for a change in the ...
Pfizer's Hympavzi received FDA approval on October 11, for the treatment of Hemophilia, which becomes the first of its ... Astellas followed suit on October 18, with Vyloy, the first ...
Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' ...
Scemblix is the first drug to show superiority over all standard of care therapies for a rare type of leukemia.
J&J is the third medtech company to gain U.S. approval for pulsed field ablation, a new atrial fibrillation treatment seeing rapid adoption.
Shares of Sangamo Therapeutics surged 69% after the genetic medicines developer announced regulatory progress in its quest to ...
FDA approves Pfizer’s Hympavzi for routine prophylaxis in hemophilia A and B patients, offering a once-weekly dosing via auto-injector pen. Phase 3 trial showed Hympavzi reduced bleeding rates ...